2023 | Austria | Randomized placebo-controlled trial
Pramhas S et al. The Lancet Regional Health Europe. 2023;35:100777.
Methods: Eighty-six adults with painful knee osteoarthritis were randomized to eight weeks of high-dose oral CBD or placebo, added to continued paracetamol. Fifty-eight participants completed the trial.
Findings: Pain improved similarly in both groups, with no significant added benefit from CBD. Adverse events were more frequent with CBD, and liver enzyme increases occurred more often in the CBD group.
Limitations: The study tested one dose strategy, one condition, and an add-on treatment over eight weeks. Attrition limits certainty. A negative result in this setting does not settle every CBD and pain question.